Account
Case Studies
01.01.2023
Gaining payer insights to inform phase III

The client required expert operational pricing support and insights during a company restructure whi...

Read more
Case Studies
01.01.2023
Developing a multi-indication budget impact model

Our client had in-licenced a hospital drug that they were seeking to launch in the EU, following a r...

Read more
Case Studies
01.01.2023
Support with the launch of an ultra-orphan drug

Our client was struggling to understand the value of their product (a single-use treatment for an ul...

Read more
Articles
08.12.2022
EU HTA – looking back on 2022

Our market access experts cover the changes to the joint EU HTA process that occurred in 2022 and wh...

Read more
Webinar
08.12.2022
Are you ready for the new EU HTA in 2025?

Webinar: Our experts discuss the latest news and updates on the EU HTA process, including the Joint ...

Read more
Publications
07.11.2022
ISPOR 2022 Plenary Session 1 - HTA and Regulation

Our experts provide a detailed summary of Plenary Session 1 at ISPOR 2022 on the Convergence of HTA ...

Read more
Insider Insights
22.08.2022
HAS announces changes to health evaluation

The Haute Autorité de Santé (HAS), recently announced changes to the conditions in which a drug wi...

Read more
News
14.07.2022
PMA Insights: Week 28

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
23.06.2022
AIFA reorganisation delayed again

It is widely expected that the reform will entail the unification of the CTS and the CPR into one bo...

Read more
Insider Insights
20.06.2022
NICE trials new proportionate approach to increase

The aim of this trial is to increase capacity, with a goal of a 20% increase by 2023-24.

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.